Oxford Immunotec Schedules First Quarter 2018 Earnings Release and Conference Call for May 1, 2018
April 17 2018 - 8:30AM
OXFORD, United Kingdom and MARLBOROUGH, Mass.,
April 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC
(Nasdaq:OXFD), a global, high-growth diagnostics company, today
announced that it plans to release first quarter 2018 financial
results prior to market open on Tuesday, May 1, 2018. Dr.
Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri,
Chief Financial Officer, will host a conference call to review the
Company's results at 8:00 a.m. Eastern Time the same day. The
call will be concurrently webcast.
To listen to the conference call on your
telephone, please dial (855) 363-5047 for United States callers or
+1 (484) 365-2897 for international callers and reference
confirmation code 9793845, approximately ten minutes prior to start
time. To access the live audio webcast or subsequent archived
recording, visit the Investor Relations section of Oxford
Immunotec's website at www.oxfordimmunotec.com. The
replay will be available on the Company's website for approximately
60 days.
About Oxford
Immunotec
Oxford Immunotec Global PLC is a global,
high-growth diagnostics company focused on developing and
commercializing proprietary tests for the management of underserved
immune-regulated conditions. The Company's first product is
the T-SPOT®.TB test, which is used to test for tuberculosis
infection. The T-SPOT.TB test has
been approved for sale in over 50 countries, including the United
States, where it has received pre-market approval from the Food and
Drug Administration, Europe, where it has obtained a CE mark, as
well as Japan and China. The Company's second product line is
a range of assays for tick-borne diseases, such as Lyme disease.
The Company is headquartered near Oxford, U.K. and in Marlborough,
Mass. Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are
trademarks of Oxford Immunotec Ltd. Immunetics is a trademark
of Immunetics, Inc.
Forward-Looking
Statements
This release contains forward-looking statements
that involve risks and uncertainties, including statements about
our anticipated plans, objectives, intentions, including effects on
future financial and operating results, prospects for sales of our
products and other statements that are not historical facts. The
forward-looking statements in this release are based on current
expectations, assumptions and data available as of the date of this
release and are subject to known and unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements, including but
not limited to: decisions by regulatory authorities, hospitals and
other health care institutions, laboratories, physicians, patients
and third party payers that could affect the Company's business and
prospects; as well as our ability to expeditiously and successfully
expand our sales and distribution networks. The risks included
above are not exhaustive. Other factors that could adversely affect
our business and prospects are described under the "Risk Factors"
section in our filings with the Securities and Exchange Commission
("SEC"). Our filings are available for free by visiting the
investor section of our website, www.oxfordimmunotec.com, or
the SEC's website, www.sec.gov.
Investors should give careful consideration to
these risks and uncertainties. Forward-looking statements contained
herein are based on current expectations and assumptions and
currently available data and are neither predictions nor guarantees
of future events or performance. You should not place undue
reliance on forward-looking statements contained herein, which
speak only as of the date of this release. We do not undertake to
update or revise any forward-looking statements after they are
made, whether as a result of new information, future events, or
otherwise, except as required by applicable law.
CONTACT:
For Media and Investor
Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Oxford Immunotec via Globenewswire
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Sep 2023 to Sep 2024